Rhode Island
Requires Coverage of Comprehensive Biomarker Testing
Yes
Highlighted Disparity
No racial disparities were found in Rhode Island for these lung cancer metrics
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Rhode Island is 59.1 and significantly higher than the national rate of 52.1.
- It ranks 37th among all states, placing it in the below average tier.
- Over the last five years, the rate of new cases in Rhode Island improved by 12%.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
Five-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Rhode Island is 39.4%, which is significantly higher than the national rate of 31.0%.
- It ranks 2nd among the 43 states with survival data, placing it in the top tier.
- Over the last five years, the survival rate in Rhode Island improved by 28%.
Early Diagnosis:
- In Rhode Island, 38.0% of cases are caught at an early stage, which is significantly higher than the national rate of 29.3%.
- It ranks 1st among the 47 states with data on diagnosis at an early stage, placing it in the top tier.
- Over the last five years, the early diagnosis rate in Rhode Island improved by 24%.
Lung Cancer Treatment
Surgical Treatment:
- Rhode Island ranked 5th (out of the 40 states with available data) with 24.8% of cases undergoing surgery as part of the first course of treatment.
- This is significantly higher than the national rate of 21.4% and puts Rhode Island in the above average tier.
No Treatment:
- Rhode Island ranked 1st (out of the 47 states with available data) with 13.4% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.9% and puts Rhode Island in the top tier.
Biomarker Coverage:
- Rhode Island was one of the 19 states that required insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2026.
Screening
Screening for High Risk:
- In Rhode Island, 31.9% of those at high risk were screened, which was not significantly different than the national rate of 24.4%.
- It ranks 5th (out of the 50 states with available data), placing it in the above average tier.
Prevention
Tobacco Use:
- The 2025 smoking rate in Rhode Island is 8.9% and significantly lower than the national rate of 10.4%.
- It ranks 12th (out of the 48 states with available data), placing it in the above average tier.
Radon:
- In Rhode Island, 21.4% of radon tests results were at or above the action level recommended by EPA.
- It ranks 22nd among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 47.9 per 100,000 population among Black individuals in Rhode Island, not significantly different than the rate of 53.5 among Black individuals nationally, and significantly lower than the rate of 62.4 among white individuals in Rhode Island.
- The five-year survival rate is 44.3% among Black individuals in Rhode Island, significantly higher than the rate of 28.5% among Black individuals nationally, and not significantly different than the rate of 38.7% among white individuals in Rhode Island.
39.0% of lung cancer cases are diagnosed at an early stage among Black individuals in Rhode Island, significantly higher than the rate of 26.3% among Black individuals nationally, and not significantly different than the rate of 38.1% among white individuals in Rhode Island.
24.4% of Black individuals with lung cancer in Rhode Island underwent surgery, not significantly different than the rate of 17.9% among Black individuals nationally, and not significantly different than the rate of 24.9% among white individuals in Rhode Island.
Lung cancer data (including lack of treatment) is incomplete or unavailable for Black individuals in Rhode Island due to data limitations.
Latino individuals:
The rate of new lung cancer cases is 25.8 per 100,000 population among Latino individuals in Rhode Island, not significantly different than the rate of 27.8 among Latino individuals nationally, and significantly lower than the rate of 62.4 among white individuals in Rhode Island.
State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 30.8%, not significantly different than the rate of 30.8% among white individuals.
- 35.9% of lung cancer cases are diagnosed at an early stage among Latino individuals in Rhode Island, significantly higher than the rate of 24.7% among Latino individuals nationally, and not significantly different than the rate of 38.1% among white individuals in Rhode Island.
- 25.4% of Latino individuals with lung cancer in Rhode Island underwent surgery, not significantly different than the rate of 22.0% among Latino individuals nationally, and not significantly different than the rate of 24.9% among white individuals in Rhode Island.
18.3% of Latino individuals with lung cancer in Rhode Island did not receive any treatment, significantly lower than the rate of 25.1% among Latino individuals nationally, and not significantly different than the rate of 13.2% among white individuals in Rhode Island.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 32.2 per 100,000 population among Asian or Pacific Islanders individuals in Rhode Island, not significantly different than the rate of 32.7 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 62.4 among white individuals in Rhode Island.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time.Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 35.4% and significantly higher than the rate of 30.8% among white individuals.
- Lung cancer data (including early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Asian or Pacific Islander individuals in Rhode Island due to data limitations.
Indigenous Peoples:
- Lung cancer data (including rates, early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Indigenous Peoples (American Indians/Alaska Natives) in Rhode Island due to data limitations.
Summary
Despite the early diagnosis rate in Rhode Island falling into the top tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Rhode Island was one of the states that required insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Rhode Island falls into the top tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 13, 2026
